Clinical Prognosis and Progression of Myasthenia Gravis Patients
Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Recruiting
- Xuan Wu Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >14.
Clinical Diagnosis of MG with supporting evidence:
- unequivocal clinical response to pyridostigmine
- positive antibody testing
- decrement >10% in repetitive nerve stimulations study (RNS) .
- Willingness to sample collection, imaging study and other disease-related examinations and assessments.
- Patients with informed consent.
Exclusion Criteria:
- History of chronic degenerative, psychiatric, or neurologic disorder other than MG that can produce weakness or fatigue.
- Age ≤14 years.
- Severe anxiety, depression or schizophrenia.
- Cognitive impairment or mini-mental state examination (MMSE) score ≤24.
- Severe systemic illness with life-expectancy less than 4 years.
- Unwillingness to consent for collection of biological samples.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Ocular MG
Patients with autoimmune MG whose symptoms restricted to extraocular muscles
|
Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Other Names:
|
|
Generalized MG
Patients not only suffer from extraocular muscles weakness but also from limb weakness, bulbar symptoms, or even respiratory failure
|
Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Conversion rates from ocular to generalized MG at the last visit and risk factors.
Time Frame: Baseline, 48 months
|
Ocular MG patients are followed up to determine the ratio of conversion to generalized disease at the end of follow-up.
The clinical records will be retrospectively analyzed to search for risk factors of progressing.
|
Baseline, 48 months
|
|
Change in Quantitative Myasthenia Gravis (QMG) Scores from Baseline to 48 months.
Time Frame: Baseline, 12 months, 24 months, 36 months, 48 months
|
The QMG is a 13-item scale which measures ocular, bulbar, limb function and respiratory function.
The total score ranges from 0 (no myasthenic findings) to 39 (maximal myasthenic deficits) obtained by summing the responses to each individual item (None=0, Mild=1, Moderate=2, Severe=3).
|
Baseline, 12 months, 24 months, 36 months, 48 months
|
|
Change in MG-specific Activities of Daily Living scale (MG-ADL).
Time Frame: Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
|
The MG-ADL is an 8-item scale to assess symptoms of myasthenia gravis patients obtained by summing the responses to each individual item (Grades: 0,1,2,3).
The score ranges from 0 to 24.
|
Baseline,3months, 6 months, 9 months, 12 months, 18 months, 24 months, 30months, 36 months, 42 months, 48 months
|
|
The proportion of patients reaching minimal manifestations (MM) or better.
Time Frame: 48 months
|
Clinical statuses of patients are assessed and categorized according to Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS).
MM or better includes Minimal Manifestation (MM), Pharmacologic Remission (PR) or Complete Remission (CR).
|
48 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Patients with Treatment-related Adverse Experiences.
Time Frame: 3 months, 6 months, 12 months, 24 months, 36 months, 48 months
|
Treatment-Related Adverse Events (AEs) are evaluated in patients of different regimens.
|
3 months, 6 months, 12 months, 24 months, 36 months, 48 months
|
|
Changes in titers of MG antibodies.
Time Frame: Baseline, 12 months, 24 months, 36 months, 48 months
|
MG antibodies are detected at enrollment and the titers of antibodies will be monitored annually.
|
Baseline, 12 months, 24 months, 36 months, 48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: yuwei Da, M.D., Xuan Wu Hospital, Capital Medical University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Anti-Bacterial Agents
- Anticonvulsants
- Antibiotics, Antineoplastic
- Antifungal Agents
- Reproductive Control Agents
- Antitubercular Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Cholinesterase Inhibitors
- Methylprednisolone
- Cyclophosphamide
- Immunoglobulins
- Immunoglobulins, Intravenous
- Prednisone
- Methotrexate
- Azathioprine
- Tacrolimus
- gamma-Globulins
- Rho(D) Immune Globulin
- Mycophenolic Acid
- Bromides
- Cyclosporine
- Cyclosporins
- Immunosuppressive Agents
- Pyridostigmine Bromide
Other Study ID Numbers
Other Study ID Numbers
- 2017YFC0907705
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.